Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.

Publication Type:

Journal Article

Source:

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 28, Issue 18, p.3023-7 (2010)

Keywords:

2010, Angiogenesis Inhibitors, Center-Authored Paper, Follow-Up Studies, Humans, Multiple Myeloma, Neoplasm Recurrence, Local, Public Health Sciences Division, Remission Induction, Survival Rate, Thalidomide, Time Factors, Treatment Outcome

Abstract:

In Total Therapy 2, after randomly assigning 323 patients with myeloma to thalidomide and 345 to a control arm, no difference was observed in overall survival, with a median follow-up of 42 months, although at 72 months, survival was superior on the thalidomide arm in the one third exhibiting cytogenetic abnormalities (CA). After further follow-up of 87 months, we examined, in reiterative analyses, the effect of increasing time intervals on clinical outcomes relevant to baseline prognostic variables and treatment randomization.